Thrivent Financial for Lutherans lifted its position in Ingevity Co. (NYSE:NGVT - Free Report) by 1.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,383,053 shares of the company's stock after purchasing an additional 23,497 shares during the quarter. Thrivent Financial for Lutherans owned 3.80% of Ingevity worth $53,939,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. First Horizon Advisors Inc. grew its holdings in Ingevity by 809.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 591 shares of the company's stock worth $26,000 after acquiring an additional 526 shares during the last quarter. Isthmus Partners LLC bought a new stake in Ingevity during the 2nd quarter worth about $35,000. Blue Trust Inc. grew its holdings in Ingevity by 101.8% during the 2nd quarter. Blue Trust Inc. now owns 896 shares of the company's stock worth $43,000 after acquiring an additional 452 shares during the last quarter. Headlands Technologies LLC bought a new stake in Ingevity during the 2nd quarter worth about $46,000. Finally, KBC Group NV grew its holdings in Ingevity by 50.8% during the 3rd quarter. KBC Group NV now owns 1,574 shares of the company's stock worth $61,000 after acquiring an additional 530 shares during the last quarter. Institutional investors own 91.59% of the company's stock.
Ingevity Stock Performance
NYSE:NGVT traded down $0.29 during trading hours on Tuesday, hitting $45.72. The stock had a trading volume of 76,264 shares, compared to its average volume of 267,625. The business's 50 day moving average is $38.34 and its 200-day moving average is $42.17. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 6.52. Ingevity Co. has a one year low of $30.90 and a one year high of $56.29.
Ingevity (NYSE:NGVT - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $1.10 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.50. The business had revenue of $376.90 million during the quarter, compared to analysts' expectations of $376.95 million. Ingevity had a negative net margin of 38.11% and a positive return on equity of 24.46%. The firm's quarterly revenue was down 15.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.21 EPS. On average, research analysts forecast that Ingevity Co. will post 2.55 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on NGVT shares. Oppenheimer cut their target price on shares of Ingevity from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. CJS Securities upgraded shares of Ingevity from a "market perform" rating to an "outperform" rating and set a $58.00 target price on the stock in a research report on Wednesday, August 7th. Wells Fargo & Company cut their target price on shares of Ingevity from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, August 5th. Finally, BMO Capital Markets upped their target price on shares of Ingevity from $40.00 to $47.00 and gave the company a "market perform" rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $52.17.
View Our Latest Analysis on Ingevity
Ingevity Company Profile
(
Free Report)
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Read More
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.